Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,137 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at $2,322,849.05. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Tarsus Pharmaceuticals Trading Up 0.1 %

Shares of TARS stock opened at $49.97 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The company’s 50-day moving average price is $48.48 and its 200-day moving average price is $45.21. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -13.12 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. As a group, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP raised its position in Tarsus Pharmaceuticals by 3.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock valued at $140,191,000 after purchasing an additional 91,451 shares during the period. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock worth $138,432,000 after purchasing an additional 321,552 shares during the last quarter. Vanguard Group Inc. raised its holdings in Tarsus Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock valued at $117,117,000 after buying an additional 17,839 shares during the period. Toronto Dominion Bank acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $105,714,000. Finally, Lord Abbett & CO. LLC boosted its stake in Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after buying an additional 685,111 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TARS. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.